期刊文献+

HPLC法测定普乐沙福原料药的有关物质 被引量:2

Determination of the Related Substances in Plerixafor by HPLC
下载PDF
导出
摘要 目的:建立普乐沙福原料药有关物质的反相离子对高效液相色谱法。方法:采用离子对反相高效液相色谱法分析,以对照品外标法定性和定量。采用沃特世Xbridge C_(18)色谱柱(250 mm×4.6 mm,5μm),流动相为pH2.0庚烷磺酸钠-乙腈(80∶20),流速1.0 ml·min^(-1),检测波长210 nm,柱温35℃,进样量10μl。结果:普乐沙福与相邻杂质之间的分离度均大于1.5;有关物质1、2、3的定量限分别为21、35、26 ng,且在各自的线性范围内线性关系良好(r≥0.999 0);平均回收率分别为99.7%,100.3%,101.2%,RSD分别为1.1%,0.8%,1.7%(n=9)。结论:该方法专属性强、准确度高,适用于普乐沙福原料药的质量控制。 Objective: To develop a novel method for the determination of the related substances in plerixafor. Methods: A re- versed-phase ion-paired HPLC method was applied in the qualitative and quantitative determination of plerixafor by an external standard method. The method was performed on a Waters Xbridge C18 column (250 mm× 4.6 mm, 5 μm) , the mobile phase consisted of 1- heptancsulfonic acid sodium salt buffer (pH 2.0) and aeetonitrile with the ratio of 80:20 (v/v), the flow rate was 1.0 ml .min-1 , the detection wavelength was 210 nm, the column temperature was 35℃ , and the injection volume was 10 ixl. Results: The degrada- tion products were well separated from the main peak, the LOQ (limits of quantitative) of the related substance 1,2 and 3 respectively was 21 ng, 35 ng and 26 ng with good linearity within respective linear range( r≥0. 999 0) , the average recovery was 99.7%, 100.3 % and 101.2%, and RSD was 1.1%, 0.8% and 1.7% , respectively (n = 9). Conclusion: The method is specific and accu- rate, which can be used for the quality control of plerixafor.
出处 《中国药师》 CAS 2016年第10期1856-1858,共3页 China Pharmacist
关键词 普乐沙福 有关物质 高效液相色谱 Plerixafor Related substances HPLC
  • 相关文献

参考文献5

二级参考文献26

  • 1谢沐风.如何建立高效液相色谱法测定有关物质的方法[J].中国医药工业杂志,2007,38(1):45-48. 被引量:61
  • 2翁建宇,杜欣,张建军,周茂华,吴穗晶,陆泽生,林伟,黄梓伦.G-CSF对供者外周血CD34^+细胞黏附分子表达的影响[J].中国输血杂志,2007,20(2):105-107. 被引量:6
  • 3Ukkipati A. Vaclavikova J. In vitro reconstitution and preparative purification of complexes between the chemokine receptor CXCR4 and its ligands SDFlalpha, gpl20-CD4 and AMD3100[ J]. Protein Expr Purif, 2006,50(2) :203- 214.
  • 4Stewart DA, Smith C. Pharmacokinetics and pharmacodynamics of plefixafor in patients with non-Hodgkin lymphoma and multiple myeloma [ J ]. Biol Blood Marrow Transplant, 2009,15 ( 1 ) : 39-46.
  • 5Lack NA, Green B, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100 [ J ]. Clin Pharmacol Ther ,2005 , 77 ( 5 ) :427-436.
  • 6Devine SM, Flomenberg N. Rapid mobilization of CD34+ cells following adminis- tration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin s lymphoma [ J ]. J Clin 0ncol,2004, 22 (6) : 1095-1102.
  • 7DiPersio JF. A Phase llI, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor) + G-CSF vs. Placebo + G-CSF in non-Hodgkins lymphoma (NHL) patients for autologous hematopoietic stem cell ( aHSC ) transplantation [J].ASH Annual Meeting Abs ,2007,110 : 601.
  • 8DiPersio J. A Phase Ili, multicenter, randomized, double-blind, placebo-con-trolled, comparative trial of AMD3100 (Plerixafor) + G-CSF vs. G-CSF + placebo for mobilization in multiple myeloma ( MM ) patients for autologous hematopoietic stem cell ( aHSC ) transplantation [ J ]. ASH Annual Meeting Abs, 21307,110:445.
  • 9Socinski MA, Cannistra SA, Elias A, et al. Glanulocyte- rnacrophage colony stimulating factor expands circulating haemopoietic progemitor cell compartment in man [J]. Lancet, 1988,1 (8596): 1194-1198.
  • 10To LB, Haylock DN, Thorp D, et al. The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia [J]. Bone Marrow Transplant, 1989, 4 (1) : 41-47.

共引文献7

同被引文献10

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部